Cardium Therapeutics and its Tissue Repair Company, Cardium, will utilize AMRI's Burlington, US, site to manufacture sterile pre-filled syringes in support of the US introduction of Excellagen, as per the signed contract agreement.
Excellagen is a sterile, syringe-based, fibrillar flowable bovine Type I collagen topical gel (2.6%) which is applied following surgical debridement procedures.
Excellagen is indicated for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds.
Cardium chairman and CEO Christopher Reinhard said, "We look forward to an ongoing and collaborative relationship with AMRI as we continue to introduce Excellagen to the U.S. market."
Excellagen is FDA-cleared and has been introduced in the US market by Cardium Therapeutics on 30 March 2012.